- Trials with a EudraCT protocol (107)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
107 result(s) found for: Norplant.
Displaying page 1 of 6.
| EudraCT Number: 2004-002872-41 | Sponsor Protocol Number: ELR100710 | Start Date*: 2005-10-18 |
| Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
| Full Title: A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis | ||
| Medical condition: Seasonal allergic rhinitis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005448-21 | Sponsor Protocol Number: H8O-EW-GWBE | Start Date*: 2006-06-30 |
| Sponsor Name:Eli Lilly and Company Ltd. | ||
| Full Title: Long-Term Treatment with Exenatide versus Glimepiride in Patients with Type 2 Diabetes Pretreated with Metformin | ||
| Medical condition: Type 2 diabetes mellitus | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) ES (Completed) DE (Completed) HU (Completed) IT (Completed) IE (Completed) AT (Completed) CZ (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000482-35 | Sponsor Protocol Number: ARA102198 | Start Date*: 2004-10-11 |
| Sponsor Name:GlaxoSmithKline Research & Development Ltd. | ||
| Full Title: A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arth... | ||
| Medical condition: Rheumatoid Arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) LT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-003238-14 | Sponsor Protocol Number: 104888, 107509 | Start Date*: 2006-09-26 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II/III, observer-blind, multicountry, multicentre, randomized study to demonstrate the superiority in terms of immunogenicity of AS25 adjuvanted influenza vaccine administered in adults age... | ||
| Medical condition: Healthy subjects, Immunization against influenza in male and female subjects aged ≥ 50 years. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) NO (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-019057-17 | Sponsor Protocol Number: SPC3649-203 | Start Date*: 2010-07-13 |
| Sponsor Name:Santaris Pharma A/S | ||
| Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered ... | ||
| Medical condition: Patients infected with chronic hepatitis C | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) DE (Completed) SK (Completed) PL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-000965-21 | Sponsor Protocol Number: 104702 | Start Date*: 2005-06-14 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formu... | ||
| Medical condition: Primary immunization of healthy adolescents/young adults against meningococcal disease due to Neisseria meningitidis (N. meningitidis) of serogroups A, C, W-135 and Y. | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-021789-31 | Sponsor Protocol Number: A3051139 | Start Date*: 2010-12-08 | |||||||||||
| Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017 US | |||||||||||||
| Full Title: A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PRE... | |||||||||||||
| Medical condition: Smoking Cessation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) GB (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-004248-37 | Sponsor Protocol Number: 103532 | Start Date*: Information not available in EudraCT |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formu... | ||
| Medical condition: Primary immunization of healthy adolescents/young adults against meningococcal disease due to Neisseria meningitidis (N. meningitidis) of serogroups A, C, W-135 and Y | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004455-52 | Sponsor Protocol Number: CP15/15 | Start Date*: 2016-04-18 |
| Sponsor Name:Cipla Europe NV | ||
| Full Title: An open label, prospective, randomized, parallel group, multicenter 4-week study to evaluate the efficacy and safety of salmeterol/ fluticasone propionate fixed dose combination following ... | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-000267-17 | Sponsor Protocol Number: VPI-103-01 | Start Date*: 2007-02-21 | |||||||||||
| Sponsor Name:Verus Pharmaceuticals Inc | |||||||||||||
| Full Title: A SINGLE CENTRE, GAMMA SCINTIGRAPHY STUDY IN ASTHMATIC PATIENTS TO COMPARE PULMONARY DEPOSITION AND PHARMACOKINETICS OF ALBUTEROL INHALATION SOLUTION (AIS) DELIVERED VIA eFLOW NEBULISER AND SALBUTA... | |||||||||||||
| Medical condition: The medical condition which is under investigation is Asthma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-000083-27 | Sponsor Protocol Number: GT-08 | Start Date*: 2004-09-19 |
| Sponsor Name:ALK-Abelló A/S | ||
| Full Title: A randomised, parallel-group, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of ALK Grass Tablet Phleum pratense in subjects with seasonal grass pollen induced r... | ||
| Medical condition: Rhinoconjunctivitis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) IT (Completed) ES (Completed) AT (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-015928-28 | Sponsor Protocol Number: ELTODYS09 | Start Date*: 2010-10-07 |
| Sponsor Name:PsychoGenics Inc | ||
| Full Title: A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease... | ||
| Medical condition: Dyskinesias related to levodopa treatment in Parkinson´s disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-002207-13 | Sponsor Protocol Number: NRA1280023 | Start Date*: 2006-06-29 |
| Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg | ||
| Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial | ||
| Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-003236-30 | Sponsor Protocol Number: 104887 | Start Date*: 2006-09-18 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vac... | ||
| Medical condition: Immunisation against influenza disease in an elderly population aged over 65 years | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-012117-21 | Sponsor Protocol Number: 112682 | Start Date*: 2009-09-29 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in adolesce... | ||
| Medical condition: Antibody persistence and hepatitis B vaccine challenge in adolescents aged 12-13 years, vaccinated in infancy with three doses of GSK Biologicals’ HBV vaccine in routine practice. | ||
| Disease: | ||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004412-70 | Sponsor Protocol Number: A3051054 | Start Date*: 2007-07-25 | |||||||||||
| Sponsor Name:PFIZER | |||||||||||||
| Full Title: A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL WITH 40-WEEK FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE FOR SMOKING CESSATION IN PATIENTS WIT... | |||||||||||||
| Medical condition: Smoking Cessation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-002783-10 | Sponsor Protocol Number: 110674 | Start Date*: 2007-09-17 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II, controlled, single centre, open study to evaluate the safety, reactogenicity and immunogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with a reduced dos... | ||
| Medical condition: Re-vaccination against influenza in male and female subjects aged 18-60 years old. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-001160-29 | Sponsor Protocol Number: NAL-II-19-1 | Start Date*: 2019-06-24 | |||||||||||
| Sponsor Name:LABORATOIRES SMB S.A | |||||||||||||
| Full Title: A single blind, placebo controlled, three period, chronic dosing (6 weeks), multicentre, exploratory study to evaluate the effects of Nacystelyn (20 mg BID and 40 mg BID) on Functional Respiratory ... | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-001281-16 | Sponsor Protocol Number: 107064, 107217 | Start Date*: 2006-05-16 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (split virus formulation conta... | ||
| Medical condition: Immunization against (H5N1) influenza disease in subjects aged 18 years and older. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) DE (Completed) ES (Completed) EE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-003477-94 | Sponsor Protocol Number: 110947 | Start Date*: 2008-02-13 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellu... | ||
| Medical condition: Booster immunisation against diphtheria, tetanus, pertussis and poliomyelitis diseases in children and adolescents. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
